Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Insulin Market

4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Insulin Market Analysis and Forecast, 2017–2031

5. Key Insights
5.1. Regulatory Scenario, by Region/globally
5.2. Key Mergers & Acquisitions
5.3. Technological Advancements
5.4. COVID-19 Pandemics Impact on Industry

6. Global Insulin Market Analysis and Forecast, by Mode of Action
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Mode of Action, 2017–2031
6.3.1. Rapid-acting
6.3.2. Short-acting
6.3.3. Intermediate-acting
6.3.4. Premixed
6.3.5. Long-acting
6.4. Market Attractiveness Analysis, by Mode of Action

7. Global Insulin market Analysis and Forecast, by Source
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Source, 2017–2031
7.3.1. Modern Insulin
7.3.2. Human Insulin
7.4. Market Attractiveness Analysis, by Source

8. Global Insulin market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region

9. North America Insulin Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Mode of Action, 2017–2031
9.2.1. Rapid-acting
9.2.2. Short-acting
9.2.3. Intermediate-acting
9.2.4. Premixed
9.2.5. Long-acting
9.3. Market Value Forecast, by Source, 2017–2031
9.3.1. Modern Insulin
9.3.2. Human Insulin
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Mode of Action
9.5.2. By Source
9.5.3. By Country

10. Europe Insulin Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Mode of Action, 2017–2031
10.2.1. Rapid-acting
10.2.2. Short-acting
10.2.3. Intermediate-acting
10.2.4. Premixed
10.2.5. Long-acting
10.3. Market Value Forecast, by Source, 2017–2031
10.3.1. Modern Insulin
10.3.2. Human Insulin
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Mode of Action
10.5.2. By Source
10.5.3. By Country/Sub-region

11. Asia Pacific Insulin Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Mode of Action, 2017–2031
11.2.1. Rapid-acting
11.2.2. Short-acting
11.2.3. Intermediate-acting
11.2.4. Premixed
11.2.5. Long-acting
11.3. Market Value Forecast, by Source, 2017–2031
11.3.1. Modern Insulin
11.3.2. Human Insulin
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Mode of Action
11.5.2. By Source
11.5.3. By Country/Sub-region

12. Latin America Insulin Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Mode of Action, 2017–2031
12.2.1. Rapid-acting
12.2.2. Short-acting
12.2.3. Intermediate-acting
12.2.4. Premixed
12.2.5. Long-acting
12.3. Market Value Forecast, by Source, 2017–2031
12.3.1. Modern Insulin
12.3.2. Human Insulin
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Mode of Action
12.5.2. By Source
12.5.3. By Country/Sub-region

13. Middle East & Africa Insulin Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Mode of Action, 2017–2031
13.2.1. Rapid-acting
13.2.2. Short-acting
13.2.3. Intermediate-acting
13.2.4. Premixed
13.2.5. Long-acting
13.3. Market Value Forecast, by Source, 2017–2031
13.3.1. Modern Insulin
13.3.2. Human Insulin
13.3.3. Infection Treatment
13.3.4. Gas Embolism
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Mode of Action
13.5.2. By Source
13.5.3. By Country

14. Competition Landscape
14.1. Market Player - Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2021
14.3. Company Profiles
14.3.1. Shanghai Fosun Pharmaceutical Co., Ltd.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Analysis
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. Tonghua Dongbao
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Analysis
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. Eli Lilly and Company
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Analysis
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. Sanofi
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Analysis
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. Novo Nordisk A/S
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Analysis
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. Julphar
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Analysis
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. Biocon Ltd.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Financial Analysis
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
14.3.8. Becton, Dickinson and Company
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Financial Analysis
14.3.8.3. Growth Strategies
14.3.8.4. SWOT Analysis
14.3.9. Ypsomed AG
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Financial Analysis
14.3.9.3. Growth Strategies
14.3.9.4. SWOT Analysis
14.3.10. Biodel Inc.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Financial Analysis
14.3.10.3. Growth Strategies
14.3.10.4. SWOT Analysis
14.3.11. B. Braun Melsungen AG
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Financial Analysis
14.3.11.3. Growth Strategies
14.3.11.4. SWOT Analysis



List of Figures

List of Figures

Figure 1: Insulin: Market Segmentation

Figure 2: Global Insulin Market Revenue (US$ Mn), by Mode of Action, 2021

Figure 3: China Insulin Market Revenue (US$ Mn), by Mode of Action, 2021

Figure 4: Value Chain: Global Insulin Market

Figure 5: Porter’s Five Forces Analysis: Global Insulin Market

Figure 6: Market Attractiveness Analysis: Global Insulin Market, by Mode of Action

Figure 7: Comparative Analysis: Global Insulin Market Revenue (US$ Mn), by Mode of Action 2021 & 2031

Figure 8: Global Short-Acting Insulin Market Revenue (US$ Mn), 2017 – 2031

Figure 9: Global Short-Acting Insulin Market Volume (tMU), 2017 – 2031

Figure 10: Global Rapid-Acting Insulin Market Revenue (US$ Mn), 2017 – 2031

Figure 11: Global Rapid-Acting Insulin Market Volume (tMU), 2017 – 2031

Figure 12: Global Afrezza Market Revenue (US$ Mn), 2017 – 2031

Figure 13: Global NN1218 Market Revenue (US$ Mn), 2017 – 2031

Figure 14: Global Long-Acting Insulin Market Revenue, 2017 – 2031

Figure 15: Global Long-Acting Insulin Market Volume (tMU), 2017 – 2031

Figure 16: Global LY2605541 Market Revenue (US$ Mn), 2017 – 2031

Figure 17: Global LY2963016 Market Revenue (US$ Mn), 2017 – 2031

Figure 18: Global MK-1293 Market Revenue (US$ Mn), 2017 – 2031

Figure 19: Global U-300 Market Revenue (US$ Mn), 2017 – 2031

Figure 20: Global IDegLira Market Revenue (US$ Mn), 2017 – 2031

Figure 21: Global Intermediate-acting Insulin Market Revenue (US$ Mn), 2017 – 2031

Figure 22: Global Intermediate-acting Insulin Market Volume (tMU), 2017 – 2031

Figure 23: Global Premixed Market Revenue (US$ Mn), 2017 – 2031

Figure 24: Global Premixed Insulin Market Volume (tMU), 2017 – 2031

Figure 25: Breakdown of insulin-dependent population in China (2009)

Figure 26: China Short-Acting Insulin Market Revenue (US$ Mn), 2017 – 2031

Figure 27: China Short-Acting Insulin Market Volume (tMU), 2017 – 2031

Figure 28: China Rapid-Acting Insulin Market Revenue (US$ Mn), 2017 – 2031

Figure 29: China Rapid-Acting Insulin Market Volume (tMU), 2017 – 2031

Figure 30: China Long-Acting Insulin Market Revenue (US$ Mn), 2017 – 2031

Figure 31: China Long-Acting Insulin Market Volume (tMU), 2017 – 2031

Figure 32: China Intermediate-Acting Insulin Market Revenue (US$ Mn), 2017 – 2031

Figure 33: China Intermediate-Acting Insulin Market Volume (tMU), 2017 – 2031

Figure 34: China Premixed Insulin Market Revenue (US$ Mn), 2017 – 2031

Figure 35: China Premixed Insulin Market Volume (tMU), 2017 – 2031

Figure 36: Global Human Insulin Market Revenue (US$ Mn), 2017 – 2031

Figure 37: Global Human Insulin Market Volume (tMU), 2017 – 2031

Figure 38: Global Modern Insulin Market Revenue (US$ Mn), 2017 – 2031

Figure 39: Global Modern Insulin Market Volume (tMU), 2017 – 2031

Figure 40: China Human Insulin Market Revenue (US$ Mn), 2017 – 2031

Figure 41: China Human Insulin Market Volume (tMU), 2017 – 2031

Figure 42: China Modern Insulin Market Revenue (US$ Mn), 2017 – 2031

Figure 43: China Modern Insulin Market Volume (tMU), 2017 – 2031

Figure 44: Global Insulin Market Share Analysis, by Key Players, 2021 (%)

Figure 45: Global Insulin Market Share Analysis, by Key Players, 2021 (%)

Figure 46: Eli Lilly and Company: Annual Revenue (US$ Mn), 2017 – 2031

Figure 47: Novo Nordisk A/S.: Annual Revenue (US$ Mn), 2017 – 2031

Figure 48: Sanofi: Annual Revenue (US$ Mn), 2017 – 2031

Figure 49: Shanghai Fosun Pharmaceutical Co., Ltd.: Annual Revenue (US$ Mn), 2017 – 2031

List of Tables

List of Tables

Table 1: Market Snapshot: Global Insulin Market

Table 2: Global Prevalence of Diabetes, by Type

Table 3: Global Insulin Market Revenue (US$ Mn), by Mode of Action, 2017–2031

Table 4: Global Insulin Market Revenue (US$ Mn), by Source, 2017–2031

Table 5: Global Insulin Market Revenue (US$ Mn), by Region, 2017–2031

Table 6: North America Insulin Market Revenue (US$ Mn), by Mode of Action, 2017–2031

Table 7: Europe Insulin Market Revenue (US$ Mn), by Mode of Action, 2017–2031

Table 8: Asia Pacific Insulin Market Revenue (US$ Mn), by Mode of Action, 2017–2031

Table 9: Latin America Insulin Market Revenue (US$ Mn), by Mode of Action, 2017–2031

Table 10: Middle East & Africa Insulin Market Revenue (US$ Mn), by Mode of Action, 2017–2031